MAIA Biotechnology Declares Clinical Progress For Novel Anticancer Agent

MAIA Biotechnology Inc, a clinical-stage biopharmaceutical organization creating designated immunotherapies for cancer, declared the highlights and key accomplishments year-to-date, including late clinical advancement for lead up-and-comer THIO, a potential first-in-class disease telomere focusing on specialist in clinical improvement to assess its movement in non-small cell lung cancer (NSCLC).

“MAIA’s new science for cancer therapy is driving a powerful value proposition for our portfolio of novel anticancer compounds,” said Vlad Vitoc, chairman and CEO. “Our most recent clinical data points to THIO’s promising disease control, response rates, and post-therapy patient benefits. Third-line treatment with THIO has significantly outperformed reported standard-of-care data in NSCLC.

“Our confidence in the science and clinical pathways for our immuno-oncology therapies continues to grow,” Dr. Vitoc added. “This week at ASCO 2024, our poster presentation and prospects for conducting studies in various geographies has generated a wealth of positive response and excitement from US and foreign oncologists and investigators about our growing cancer treatment business.”

THIO's double component of activity is intended to prompt telomeric DNA harm and lift cancer-specific immune reactions. In the phase 2 THIO-101 clinical trial, patients with advanced non-small cell lung cancer (NSCLC) who had failed two or more standard-of-care treatment regimens prior to receiving THIO are tested on THIO sequenced with an immune checkpoint inhibitor (CPI), cemiplimab. MAIA effectively got a high worth clinical supply agreement for the cemiplimab utilized all through the THIO-101 trial.